TY - JOUR
T1 - Microbiome Profiling of Enterotoxigenic Escherichia coli (ETEC) Carriers Highlights Signature Differences between Symptomatic and Asymptomatic Individuals
AU - Higginson, Ellen E.
AU - Abu Sayeed, M.
AU - Dias, Joana Pereira
AU - Shetty, Vignesh
AU - Ballal, Mamatha
AU - Srivastava, Sunil Kumar
AU - Willis, Ian
AU - Qadri, Firdausi
AU - Dougan, Gordon
AU - Mutreja, Ankur
N1 - Funding Information:
At the University of Cambridge, this work was funded by the NIHR AMR Research Capital Funding Scheme (NIHR 200640). This work was also supported by the icddr,b, which is grateful to the governments of Bangladesh, Canada, Sweden, and the United Kingdom for providing core/unrestricted support. G.D. and A.M. were supported by NIHR-BRC. A.M. was also funded by the DBT-Cambridge partnership. Additional support was provided by Wellcome Trust Strategic Award (no. 106158/Z/14/Z) and the Bill and Melinda Gates Foundation (no. 617 OPP1141321).
Funding Information:
We thank the clinical and laboratory teams at the International Centre for Diarrheal Disease Research, Bangladesh, and the sequencing team at the Wellcome Sanger Institute for their assistance. The samples and data collected for this study were collected as part of the ETEC ETVAX Vaccine Trial (ClinicalTrials registration no. NCT02531802). We declare we have no competing interests. At the University of Cambridge, this work was funded by the NIHR AMR Research Capital Funding Scheme (NIHR 200640). This work was also supported by the icddr,b, which is grateful to the governments of Bangladesh, Canada, Sweden, and the United Kingdom for providing core/unrestricted support. G.D. and A.M. were supported by NIHR-BRC. A.M. was also funded by the DBT-Cambridge partnership. Additional support was provided by Wellcome Trust Strategic Award (no. 106158/Z/14/Z) and the Bill and Melinda Gates Foundation (no. 617 OPP1141321). Authors contributions: E.E.H.: investigation, data analysis, writing-original draft, and editing. M.A.S.: investigation, writing-review, and editing. J.P.D.: data analysis, writing-review, and editing. V.S.: writing-review and editing. M.B.: writing-review and editing. S.K.S.: writing-review and editing. I.W.: conceptualization and writing-review. F.Q.: conceptualization, funding, writing-review, and editing. G.D.: conceptualization, supervision, funding, writing-review, and editing. A.M.: conceptualization, supervision, funding, writing-review, and editing.
Publisher Copyright:
© 2022 Higginson et al.
PY - 2022/6
Y1 - 2022/6
N2 - Enterotoxigenic Escherichia coli (ETEC) is an important cause of diarrhea in children in low- and middle-income countries (LMICs). However, large-scale pathogen burden studies in children have identified ETEC in the guts of both symptomatic patients and controls. The factors that influence this balance are poorly understood, but it is postulated that the gut microbiome may play a role in either resistance or progression to disease. In this study, we profiled the microbiomes of children and adults from Bangladesh who were asymptomatically or symptomatically infected with ETEC. Symptomatic patients had significantly higher numbers of sequenced reads mapping to both E. coli and two ETEC toxins, suggesting higher bacterial burden. They were also significantly more likely to be coinfected with enteroaggregative E. coli (EAEC) and had higher proportions of other Gammaproteobacteria, including Klebsiella, Salmonella, and Haemophilus. Colonization with ETEC was also associated with increased prevalence of antimicrobial resistance (AMR) genes, most notably those of the b-lactamase class. Taxonomic profiles were distinctly different between all groups in both species richness and composition, although the direction of these changes was different in adults and children. As seen previously, children with high E. coli burdens also had higher proportions of Streptococcus spp., while healthy children were more heavily colonized by Bifidobacterium spp. Our study provides insight into the microbiome changes that occur upon infection with ETEC in an endemic setting and provides rationale for future studies investigating how the microbiome may protect or predispose individuals to symptomatic infections with gastrointestinal pathogens.
AB - Enterotoxigenic Escherichia coli (ETEC) is an important cause of diarrhea in children in low- and middle-income countries (LMICs). However, large-scale pathogen burden studies in children have identified ETEC in the guts of both symptomatic patients and controls. The factors that influence this balance are poorly understood, but it is postulated that the gut microbiome may play a role in either resistance or progression to disease. In this study, we profiled the microbiomes of children and adults from Bangladesh who were asymptomatically or symptomatically infected with ETEC. Symptomatic patients had significantly higher numbers of sequenced reads mapping to both E. coli and two ETEC toxins, suggesting higher bacterial burden. They were also significantly more likely to be coinfected with enteroaggregative E. coli (EAEC) and had higher proportions of other Gammaproteobacteria, including Klebsiella, Salmonella, and Haemophilus. Colonization with ETEC was also associated with increased prevalence of antimicrobial resistance (AMR) genes, most notably those of the b-lactamase class. Taxonomic profiles were distinctly different between all groups in both species richness and composition, although the direction of these changes was different in adults and children. As seen previously, children with high E. coli burdens also had higher proportions of Streptococcus spp., while healthy children were more heavily colonized by Bifidobacterium spp. Our study provides insight into the microbiome changes that occur upon infection with ETEC in an endemic setting and provides rationale for future studies investigating how the microbiome may protect or predispose individuals to symptomatic infections with gastrointestinal pathogens.
UR - http://www.scopus.com/inward/record.url?scp=85133143947&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133143947&partnerID=8YFLogxK
U2 - 10.1128/mbio.00157-22
DO - 10.1128/mbio.00157-22
M3 - Article
C2 - 35536001
AN - SCOPUS:85133143947
SN - 2161-2129
VL - 13
JO - mBio
JF - mBio
IS - 3
ER -